OPPM
Opus Point Partners Management Portfolio holdings
AUM
$46.9M
This Quarter Return
+2.69%
1 Year Return
-4.17%
3 Year Return
+83.22%
5 Year Return
+175.29%
10 Year Return
–
AUM
$47.7M
AUM Growth
+$47.7M
(-50%)
Cap. Flow
-$50.4M
Cap. Flow
% of AUM
-105.77%
Top 10 Holdings %
Top 10 Hldgs %
55.31%
Holding
62
New
1
Increased
14
Reduced
32
Closed
10
Top Buys
| 1 |
ProShares Ultra NASDAQ Biotechnology
BIB
|
$3.14M |
| 2 |
Acadia Pharmaceuticals
ACAD
|
$670K |
| 3 |
FibroGen
FGEN
|
$641K |
| 4 |
ALXN
Alexion Pharmaceuticals Inc
ALXN
|
$479K |
| 5 |
TSRO
TESARO, Inc.
TSRO
|
$371K |
Top Sells
| 1 |
Nektar Therapeutics
NKTR
|
$7.29M |
| 2 |
Bristol-Myers Squibb
BMY
|
$5.52M |
| 3 |
Merck
MRK
|
$4.71M |
| 4 |
RXDX
Ignyta, Inc.
RXDX
|
$4.55M |
| 5 |
AstraZeneca
AZN
|
$4.16M |
Sector Composition
| 1 | Healthcare | 68.52% |
| 2 | Real Estate | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
ProShares Ultra NASDAQ Biotechnology
BIB
$53.6M
| $10.3M | 20.26% | 187,610 +57,110 | +44% | +$3.14M |
|
|
2
Nektar Therapeutics
NKTR
$568M
| $2.49M | 4.88% | 23,431 -68,639 | -75% | -$7.29M |
|
3
SPDR S&P Biotech ETF
XBI
$5.07B
| $2.09M | 4.1% | 23,800 -41,200 | -63% | -$3.61M |
|
4
Mettler-Toledo International
MTD
$26.8B
| $2.07M | 4.05% | 3,594 | – | – |
|
5
iShares Biotechnology ETF
IBB
$5.6B
| $2M | 3.92% | 18,750 -18,750 | -50% | -$2M |
|
6
Alnylam Pharmaceuticals
ALNY
$58.5B
| $1.63M | 3.2% | 13,680 -29,384 | -68% | -$3.5M |
|
|
ALXN
7
DELISTED
Alexion Pharmaceuticals Inc
ALXN
| $1.54M | 3.03% | 13,853 +4,295 | +45% | +$479K |
|
8
Vertex Pharmaceuticals
VRTX
$100B
| $1.5M | 2.95% | 9,224 -7,415 | -45% | -$1.21M |
|
9
Alkermes
ALKS
$4.78B
| $1.41M | 2.77% | 24,333 -19,430 | -44% | -$1.13M |
|
10
Agios Pharmaceuticals
AGIO
$2.19B
| $1.31M | 2.57% | 16,002 -12,702 | -44% | -$1.04M |
|
11
Illumina
ILMN
$15.8B
| $1.3M | 2.55% | 5,506 -4,211 | -43% | -$996K |
|
|
SGEN
12
DELISTED
Seagen Inc. Common Stock
SGEN
| $1.11M | 2.17% | 21,126 -14,542 | -41% | -$761K |
|
13
Qiagen
QGEN
$10.1B
| $1.07M | 2.1% | 33,165 -23,280 | -41% | -$752K |
|
14
Ionis Pharmaceuticals
IONS
$6.79B
| $1.02M | 2% | 23,133 -16,255 | -41% | -$717K |
|
15
Amgen
AMGN
$155B
| $990K | 1.94% | 5,805 -4,119 | -42% | -$702K |
|
16
Biogen
BIIB
$19.4B
| $963K | 1.89% | 3,517 -2,276 | -39% | -$623K |
|
17
Incyte
INCY
$16.5B
| $940K | 1.84% | 11,278 -7,040 | -38% | -$587K |
|
18
Regeneron Pharmaceuticals
REGN
$61.5B
| $903K | 1.77% | 2,622 -1,454 | -36% | -$501K |
|
19
BioMarin Pharmaceuticals
BMRN
$11.2B
| $864K | 1.69% | 10,656 -6,462 | -38% | -$524K |
|
|
CELG
20
DELISTED
Celgene Corp
CELG
| $849K | 1.67% | 9,512 -5,028 | -35% | -$449K |
|
|
21
FibroGen
FGEN
$47.8M
| $845K | 1.66% | 18,281 +13,858 | +313% | +$641K |
|
|
22
Acadia Pharmaceuticals
ACAD
$4.38B
| $825K | 1.62% | 36,733 +29,853 | +434% | +$670K |
|
|
LOXO
23
DELISTED
Loxo Oncology, Inc
LOXO
| $796K | 1.56% | 6,900 -6,900 | -50% | -$796K |
|
|
CLVS
24
DELISTED
Clovis Oncology, Inc.
CLVS
| $686K | 1.35% | 13,000 -2,000 | -13% | -$106K |
|
25
Karyopharm Therapeutics
KPTI
$61.7M
| $671K | 1.32% | 50,000 -50,000 | -50% | -$671K |
|